# Comparative Study of Rosuvastatin/Ezetimib 20/10 mg and Atovastatin/Ezetimib 40/10 mg (TOLERANT Trial)

Study · id `cardio:ct-nct05910476` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05910476](<https://clinicaltrials.gov/study/NCT05910476>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05910476

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT05910476. Randomized; no masking; primary purpose treatment. Start 2023-05-03 (actual); primary completion 2026-09-22 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT05910476, source copy `cardio:ctgov-nct05910476-2025-11-25`, retrieved 2026-10-26)
- Started: 2023-05-03 (actual) (ClinicalTrials.gov record NCT05910476, source copy `cardio:ctgov-nct05910476-2025-11-25`, retrieved 2026-10-26)
- Primary completion: 2026-09-22 (anticipated) (ClinicalTrials.gov record NCT05910476, source copy `cardio:ctgov-nct05910476-2025-11-25`, retrieved 2026-10-26)
- Completion: 2026-09-22 (anticipated) (ClinicalTrials.gov record NCT05910476, source copy `cardio:ctgov-nct05910476-2025-11-25`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT05910476, source copy `cardio:ctgov-nct05910476-2025-11-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05910476-2025-11-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparative Study of Rosuvastatin/Ezetimib 20/10 mg and Atovastatin/Ezetimib 40/10 mg (TOLERANT Trial)
- Condition: Coronary Artery Disease
- Condition: Dyslipidemias
- Intervention (Drug): a high dose of statin/ezetimib
- Lead sponsor: Yonsei University
- Lead sponsor class: OTHER
- Collaborator: dotter
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Yonsei University (`cardio:org-yonsei-university`)

## Provenance

Content hash: 653efbbe7356f192d08b76711e873055c01e0f159ba008c74a5cdefc798c6f95
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
